Short-term side effects of BNT162b2 vaccine in primary care settings in Qatar: a retrospective study

Short-term side effects of BNT162b2 vaccine in primary care settings in Qatar: a retrospective study

BackgroundDespite the established effectiveness of the BNT162b2 Vaccine, the novel technology demands careful safety monitoring. While global studies have explored its safety, local data remains limited and exhibits some variability. This study investigated short-term side effects among BNT162b2 vac...

Full description

Bibliographic Details
Main Authors:	Sami Abdeen, Muna Abed Alah, Manal Al-Zaidan, Mohamed Izham Mohamed Ibrahim, Jazeel Abdulmajeed, Asma Ali Al-Nuaimi, Mohamed Ghaith Al-Kuwari
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-04-01
Series:	Frontiers in Public Health
Subjects:	COVID-19 BNT162b2 vaccine side effects primary care Qatar
Online Access:	https://www.frontiersin.org/articles/10.3389/fpubh.2024.1384327/full

Similar Items

Post-COVID-19 syndrome, who at risk and why: an insight from Qatar 2022
by: Nada Adli, et al.
Published: (2024-04-01)

Comparative effectiveness and safety of BNT162b2 and CoronaVac in Hong Kong: A target trial emulation
by: Eric Yuk Fai Wan, et al.
Published: (2024-09-01)

Prevalence and determinants of burnout syndrome among primary healthcare physicians in Qatar
by: L. Abdulla, et al.
Published: (2011-08-01)

Systems biology analysis reveals distinct molecular signatures associated with immune responsiveness to the BNT162b COVID-19 vaccineResearch in context
by: Ivan Odak, et al.
Published: (2024-01-01)

Correlation between Adverse Events and Antibody Titers among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 Vaccine
by: Itzchak Levy, et al.
Published: (2022-07-01)

Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination
by: Timothy E. Albertson, et al.
Published: (2024-03-01)

Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis
by: Eli Magen, et al.
Published: (2022-07-01)

Safety and Humoral and Cellular Immunogenicity of the BNT162b2 SARS-CoV-2 Vaccine in Liver-Transplanted Adolescents Compared to Healthy Adolescents
by: Palittiya Sintusek, et al.
Published: (2022-08-01)

Medium-term immunogenicity of three doses of BNT162b2 and CoronaVac in Hong Kong neuromuscular disease patients
by: Michael Kwan Leung Yu, et al.
Published: (2024-12-01)

Anti-SARS-CoV-2 spike antibody response to the third dose of BNT162b2 mRNA COVID-19 vaccine and associated factors in Japanese hemodialysis patients
by: Keiji Hirai, et al.
Published: (2024-05-01)

Reports of Batch-Dependent Suspected Adverse Events of the BNT162b2 mRNA COVID-19 Vaccine: Comparison of Results from Denmark and Sweden
by: Vibeke Manniche, et al.
Published: (2024-08-01)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
by: Hazal Cansu Çulpan, et al.
Published: (2023-12-01)

Antibody responses after BNT162b2 vaccination in Japanese geriatric intermediate care facilities
by: Asae Suita, et al.
Published: (2023-12-01)

Neutralizing Antibodies Responses against SARS-CoV-2 in a Sardinian Cohort Group Up to 9 Months after BNT162b2 Vaccination
by: Giuseppina Sanna, et al.
Published: (2022-03-01)

Gut microbiota is associated with persistence of longer-term BNT162b2 vaccine immunogenicity
by: Ho Yu Ng, et al.
Published: (2025-02-01)

Efficacy of BNT162b2 and CoronaVac in patients diagnosed with COVID-19
by: Dogan Mustafa, et al.
Published: (2023-06-01)

BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection?
by: Abbass Darwich, et al.
Published: (2022-04-01)

Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age
by: Joel M. Neutel, et al.
Published: (2025-02-01)

Effectiveness, Adverse Events, and Immune Response Following Double Vaccination with BNT162b2 in Staff at the National Comprehensive Cancer Center (NCCC)
by: Patrik Palacka, et al.
Published: (2022-04-01)

Acute hemorrhagic leukoencephalitis following the first dose of BNT162b2 vaccine against SARS-CoV-2: A case report
by: Konstantinos Kalafatakis, et al.
Published: (2024-02-01)

EPIDEMIOLOGY OF MALARIA IN THE STATE OF QATAR, 2008-2015
by: Elmoubasher Farag, et al.
Published: (2018-09-01)

BioNTech COVID-19 (BNT162b2) Vaccination and Varicella Zoster Reactivation: A Comprehensive Cross-sectional Study
by: Shir Azrielant, et al.
Published: (2024-02-01)

Proteomic and serologic assessments of responses to mRNA-1273 and BNT162b2 vaccines in human recipient sera
by: Thomas E. Hickey, et al.
Published: (2025-01-01)

Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents
by: Suyanee Mansanguan, et al.
Published: (2022-08-01)

Assessing the impact of annual health screenings in identifying noncommunicable disease risk factors within Qatar’s primary health care corporation Qatari registered population
by: Samya Ahmad Al-Abdulla, et al.
Published: (2024-05-01)

Waning effectiveness against COVID-19-related hospitalization, severe complications, and mortality with two to three doses of CoronaVac and BNT162b2: a case–control study
by: Vincent Ka Chun Yan, et al.
Published: (2023-12-01)

High SARS-CoV-2 antibody levels after three consecutive BNT162b2 booster vaccine doses in nursing home residents
by: Marloes I Hofstee, et al.
Published: (2025-01-01)

Effectiveness of BNT162b2 BA.4/5 Bivalent COVID-19 Vaccine against Long COVID Symptoms: A US Nationwide Study
by: Manuela Di Fusco, et al.
Published: (2024-02-01)

Reduced Neutralization Efficacy against Omicron Variant after Third Boost of BNT162b2 Vaccine among Liver Transplant Recipients
by: Yana Davidov, et al.
Published: (2023-01-01)

Immunogenicity of mRNA-1273 and BNT162b2 in Immunocompromised Patients: Systematic Review and Meta-analysis Using GRADE
by: Sushma Kavikondala, et al.
Published: (2024-05-01)

SARS-CoV-2 Gamma and Delta Variants of Concern Might Undermine Neutralizing Activity Generated in Response to BNT162b2 mRNA Vaccination
by: Luigia Trabace, et al.
Published: (2022-04-01)

Rare Adverse Events Associated with BNT162b2 mRNA Vaccine (Pfizer-BioNTech): A Review of Large-Scale, Controlled Surveillance Studies
by: Shin-Jie Yong, et al.
Published: (2022-07-01)

Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments
by: Abed Agbarya, et al.
Published: (2023-09-01)

Comparative Characterization of Human Antibody Response Induced by BNT162b2 Vaccination vs. SARS-CoV-2 Wild-Type Infection
by: Theano Lagousi, et al.
Published: (2022-07-01)

Allergy to PEG (polyethylene glycol) – sensitivity of basophil activation test with COVID-19 mRNA-vaccine BNT162B2
by: Bernadette Eberlein, et al.
Published: (2024-12-01)

Motivators and barriers of seasonal influenza vaccination among primary health care physicians in Qatar
by: Kamran Aziz, et al.
Published: (2024-02-01)

Genome-wide association study of BNT162b2 vaccine-related myocarditis identifies potential predisposing functional areas in Hong Kong adolescents
by: Chun Hing She, et al.
Published: (2024-06-01)

COVID-19 Outbreak and BNT162b2 mRNA Vaccination Coverage in a Correctional Facility during Circulation of the SARS-CoV-2 Omicron BA.1 Variant in Italy
by: Angela Stufano, et al.
Published: (2022-07-01)

Modelling the Relative Vaccine Efficacy of ARCT-154, a Self-Amplifying mRNA COVID-19 Vaccine, versus BNT162b2 Using Immunogenicity Data
by: Van Hung Nguyen, et al.
Published: (2024-10-01)

Shaping the future of primary healthcare: Factors influencing medical students’ preference for family medicine specialty in Qatar
by: Maryam A. Al-Rashid, et al.
Published: (2025-01-01)